FDA approves bluebird bio's Zynteglo gene therapy for beta thalassemia; shares up 7%

Aug. 17, 2022 1:57 PM ETbluebird bio, Inc. (BLUE)By: Jonathan Block, SA News Editor6 Comments

Beta thalassemia term with stethoscope. medical concept

Md Saiful Islam Khan

Note: This article has been updated with bluebird bio share movement and the company's reimbursement program with payers.

  • The U.S. FDA has approved bluebird bio's (NASDAQ:BLUE) Zynteglo (betibeglogene autotemcel), a gene therapy for the treatment of

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.